质子束放疗用于不可切除及医学上无法手术的局部晚期胰腺癌:多机构前瞻性登记研究结果
该多机构前瞻性登记研究纳入19例不可手术的局部晚期胰腺癌患者,接受根治性质子束放疗,中位剂量54 Gy/30次。无≥3级急性或慢性治疗相关不良事件,中位总生存14.6个月,2年无局部区域复发率81.7%。作者认为耐受性良好且疾病控制与生存与剂量递增光子放疗相当,但结论受样本量限制。
要点
- 19例局部晚期胰腺癌患者接受质子束放疗,无≥3级急性或慢性治疗相关不良事件。
- 中位总生存14.6个月,中位无局部区域复发生存11.0个月,2年无局部区域复发率81.7%。
- 作者认为质子束放疗耐受性良好且疾病控制与生存与剂量递增光子放疗相当,但结论受样本量限制。
核心结论
- 质子束放疗用于局部晚期胰腺癌耐受性良好,疾病控制与生存率与剂量递增光子放疗相当。
- 这些发现与质子治疗已知的物理和剂量学优势一致,但结论受患者样本量限制。
- 需要进一步开展纳入剂量递增质子束放疗的临床研究,以评估这些剂量学优势能否转化为有临床意义的获益。
研究设计与样本
- 多机构前瞻性登记研究,2013年3月至2019年11月纳入7家机构的19例不可手术局部晚期胰腺癌患者。
- 患者接受根治性质子束放疗,中位剂量/分次为54 Gy/30次(范围50.4-60.0 Gy/19-33次)。
- 大多数患者接受过既往化疗(68.4%)或同步化疗(78.9%)。
- 采用美国国家癌症研究所不良事件通用术语标准4.0版前瞻性评估毒性。
- 对腺癌队列(17例)采用Kaplan-Meier分析总生存、无局部区域复发生存、至局部区域复发时间、无远处转移生存及至新进展或转移时间。
主要发现
- 无患者发生≥3级急性或慢性治疗相关不良事件。
- 1级和2级不良事件分别发生于78.7%和21.3%的患者。
- 中位总生存、无局部区域复发生存、无远处转移生存及至新进展或转移时间分别为14.6、11.0、11.0和13.9个月。
- 2年无局部区域复发率为81.7%。
- 所有患者均完成治疗,其中1例因放置支架需要放疗中断。
局限性
- 原文指出结论受患者样本量限制。
- 原文指出需要进一步开展纳入剂量递增质子束放疗的临床研究,以评估这些剂量学优势能否转化为有临床意义的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Compared with photon-based techniques, proton beam radiation therapy (PBT) may improve the therapeutic ratio of radiation therapy (RT) for locally advanced pancreatic cancer (LAPC), but available data have been limited to single-institutional experiences. This study examined the toxicity, survival, and disease control rates among patients enrolled in a multi-institutional prospective registry study and treated with PBT for LAPC. METHODS AND MATERIALS: Between March 2013 and November 2019, 19 patients with inoperable disease across 7 institutions underwent PBT with definitive intent for LAPC. Patients received a median radiation dose/fractionation of 54 Gy/30 fractions (range, 50.4-60.0 Gy/19-33 fractions). Most received prior (68.4%) or concurrent (78.9%) chemotherapy. Patients were assessed prospectively for toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Kaplan-Meier analysis was used to analyze overall survival, locoregional recurrence-free survival, time to locoregional recurrence, distant metastasis-free survival, and time to new progression or metastasis for the adenocarcinoma cohort (17 patients). RESULTS: No patients experienced grade ≥3 acute or chronic treatment-related adverse events. Grade 1 and 2 adverse events occurred in 78.7% and 21.3% of patients, respectively. Median overall survival, locoregional recurrence-free survival, distant metastasis-free survival, and time to new progression or metastasis were 14.6, 11.0, 11.0, and 13.9 months, respectively. Freedom from locoregional recurrence at 2 years was 81.7%. All patients completed treatment with one requiring a RT break for stent placement. CONCLUSIONS: Proton beam RT for LAPC offered excellent tolerability while still maintaining disease control and survival rates comparable with dose-escalated photon-based RT. These findings are consistent with the known physical and dosimetric advantages offered by proton therapy, but the conclusions are limited owing to the patient sample size. Further clinical studies incorporating dose-escalated PBT are warranted to evaluate whether these dosimetric advantages translate into clinically meaningful benefits.
引用
- Eckstein J, Choi JI, Lozano A, et al. Proton Therapy for Unresectable and Medically Inoperable Locally Advanced Pancreatic Cancer: Results From a Multi-Institutional Prospective Registry. Adv Radiat Oncol. 2023. PMID: 37408677. doi:10.1016/j.adro.2023.101250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。